Atypical antipsychotics work by blocking both dopamine and serotonin receptors in the brain, a dual action that sets them apart from older antipsychotics, which target dopamine alone. This broader approach helps manage a wider range of psychiatric symptoms while generally causing fewer movement-related side effects. But the full picture is more nuanced than “blocks two receptors instead of one,” and understanding how these drugs interact with your brain chemistry explains both their benefits and their side effects.
Dopamine and Serotonin: The Core Mechanism
Older antipsychotics like haloperidol work almost exclusively by blocking dopamine D2 receptors. Dopamine overactivity in certain brain pathways drives symptoms like hallucinations and delusions, so dampening that signal helps. The problem is that dopamine does a lot of other things too. Blocking it broadly causes movement problems (stiffness, tremors, involuntary muscle contractions), raises levels of the hormone prolactin, and can actually worsen symptoms like emotional flatness and social withdrawal.
Atypical antipsychotics still block D2 receptors, but they also block serotonin receptors, particularly the 5-HT2A receptor. In many of these drugs, the affinity for serotonin receptors is comparable to or even higher than their affinity for dopamine receptors. This serotonin blockade appears to counterbalance some of dopamine blockade’s unwanted effects, particularly in brain regions that control movement and motivation. The result is that psychotic symptoms are reduced without as much disruption to the brain’s other dopamine-dependent functions.
This dual action also explains why atypical antipsychotics are effective for mood disorders. Older antipsychotics showed little benefit for depression or bipolar lows unless psychosis was also present. By engaging the serotonin system more directly, atypical antipsychotics gained a foothold in treating bipolar depression and, in some cases, major depression. Several have FDA approval specifically for bipolar depression, including quetiapine (approved in 2004), lurasidone, cariprazine, and lumateperone.
Why They Cause Fewer Movement Side Effects
One influential theory focuses not on which receptors these drugs bind to, but on how quickly they let go. Research has shown that the single most powerful predictor of whether an antipsychotic behaves “atypically” is how fast it detaches from the D2 receptor. Drugs that grip the receptor tightly and hold on (like haloperidol) leave little room for the brain’s own dopamine to get through. Drugs that bind and release quickly are more accommodating of normal dopamine signaling.
Think of it like a bouncer at a door. A typical antipsychotic stands in the doorway and doesn’t move, blocking everything. An atypical antipsychotic steps aside periodically, letting some natural dopamine traffic pass. This “loose” binding style allows the drug to reduce excessive dopamine activity (which causes psychosis) while still permitting enough normal dopamine function to avoid triggering muscle stiffness, tremors, or the restless movements known as tardive dyskinesia.
Partial Agonists: A Different Strategy
Some newer atypical antipsychotics take an entirely different approach to the dopamine problem. Instead of simply blocking the D2 receptor, drugs like aripiprazole, brexpiprazole, and cariprazine act as partial agonists. This means they can both activate and block the receptor depending on what’s happening around them.
In parts of the brain where dopamine is too active, these drugs compete with dopamine and dial the signal down. In parts where dopamine is too low, they provide a mild boost. The net effect is stabilization rather than blanket suppression. Each of these drugs has a slightly different profile. Aripiprazole activates the D2 receptor at about 60% of dopamine’s full strength, brexpiprazole at about 45%, and cariprazine at roughly 30%. These differences influence how each drug feels to the person taking it and which symptoms it targets best. Cariprazine also has an unusually strong affinity for D3 receptors, which are thought to play a role in motivation, cognition, and negative symptoms like social withdrawal.
Positive Symptoms, Negative Symptoms, and Mood
Schizophrenia involves two broad categories of symptoms. Positive symptoms are experiences that are “added” by the illness: hallucinations, delusions, disorganized thinking. Negative symptoms are things the illness takes away: motivation, the ability to feel pleasure, emotional expressiveness, and social engagement. Older antipsychotics are effective against positive symptoms but do little for negative ones. In fact, by broadly suppressing dopamine, they can make negative symptoms worse.
Atypical antipsychotics treat both. Their serotonin blockade and, in some cases, interaction with other receptor types (including certain adrenaline receptors) contribute to partial improvements in negative and cognitive symptoms. This is a meaningful clinical difference. A person on an older antipsychotic might stop hearing voices but still feel unable to connect with others or pursue goals. An atypical antipsychotic is more likely to address both sides of the equation, though negative symptoms remain the hardest to treat fully.
Why Some Cause Weight Gain and Blood Sugar Problems
Atypical antipsychotics interact with many receptor types beyond dopamine and serotonin, and some of those interactions create metabolic side effects. Two receptors are especially important here: the histamine H1 receptor and the muscarinic M3 receptor.
Histamine H1 receptors are concentrated in areas of the brain that regulate hunger and energy expenditure. When a drug blocks these receptors, appetite increases and metabolism can slow, leading to weight gain. The pattern across drugs is strikingly consistent with their H1 binding strength. Clozapine and olanzapine bind most strongly to H1 receptors and cause the most weight gain. Quetiapine and risperidone have moderate affinity and moderate effects. Aripiprazole and ziprasidone have very low H1 affinity and cause little to no weight gain.
The M3 muscarinic receptor sits on insulin-producing cells in the pancreas and plays a direct role in regulating blood sugar. When a drug blocks this receptor, insulin release is impaired and blood glucose rises. Again, clozapine and olanzapine have the highest M3 binding affinity and carry the greatest risk of elevated blood sugar and type 2 diabetes. This is why people taking these specific medications are typically monitored with regular blood work for glucose and cholesterol levels.
Prolactin: Not All Atypicals Are Equal
Dopamine normally keeps prolactin levels in check by acting on the pituitary gland. When an antipsychotic blocks dopamine receptors in this part of the brain, prolactin rises. Elevated prolactin can cause missed periods, breast tenderness or enlargement, sexual dysfunction, and over time, reduced bone density.
Most atypical antipsychotics cause less prolactin elevation than older drugs because of their looser D2 binding or their serotonin activity. But risperidone is a notable exception. It causes a rapid, dose-dependent rise in prolactin similar to haloperidol, because it binds D2 receptors tightly and doesn’t spare the pituitary pathway the way other atypicals do. Over 90% of people taking risperidone show elevated prolactin, compared to roughly half of those on olanzapine, and the elevation with risperidone tends to be sustained rather than transient. Partial agonists like aripiprazole can actually lower prolactin levels, since they mildly activate rather than block the receptor in the pituitary.
A New Mechanism: Targeting Muscarinic Receptors
In September 2024, the FDA approved the first antipsychotic that works without directly blocking dopamine receptors at all. This drug combines xanomeline, which activates muscarinic M1 and M4 receptors in the brain, with trospium, a compound that blocks muscarinic receptors outside the brain to prevent side effects like nausea and excessive salivation.
By activating M1 and M4 receptors, xanomeline indirectly modulates dopamine activity rather than blocking it head-on. The precise mechanism is still being studied, but the clinical results in schizophrenia trials were strong enough to earn approval. This represents a fundamentally different approach: adjusting dopamine indirectly through a separate signaling system, rather than standing at the dopamine receptor itself. Because it avoids direct D2 blockade, this new class may sidestep many of the traditional side effects like movement problems, prolactin elevation, and metabolic disruption, though long-term data are still accumulating.